Mortality and recurrence patterns of breast cancer patients diagnosed under a screening programme versus comparable non-screened breast cancer patients from the same population: analytical survey from 2002 to 2012

详细信息    查看全文

• 作者：A. García Fernández (1) (16) (2)
  C. Chabrera (3) (4)
  M. García Font (5)
  M. Fraile (6)
  J. M. Lain (7)
  S. Gónzalez (8)
  C. Corral (7)
  M. Torras (1)
  J. Torres (9)
  M. Teixido (10)
  I Barco (1)
  R. López (11)
  C. Gónzalez (12)
  A. Pessarrodona (13)
  N. Giménez (14) (15)
  
• 关键词：Breast neoplasms ; Mass screening ; Mortality
• 刊名：Tumor Biology
• 出版年：2014
• 出版时间：March 2014
• 年：2014
• 卷：35
• 期：3
• 页码：1945-1953
• 全文大小：186 KB
• 参考文献：1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374-03. CrossRef
  2. National Cancer Institute (2013) SEER stat fact sheets: breast. http://seer.cancer.gov/statfacts/html/breast.html. Accessed 17 Apr 2013.
  3. Baum M, Ravdin PM. Decision-making in early breast cancer: guidelines and decision tools. Eur J Cancer. 2002;38:745-. CrossRef
  4. Silverstein MJ, Skinner KA, Lomis TJ. Predicting axillary nodal positivity in 2282 patients with breast carcinoma. World J Surg. 2001;25:767-2. CrossRef
  5. Da B, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784-2. CrossRef
  6. Kopans DB. Beyond randomized controlled trials: organized mammographic screening substantially reduces breast carcinoma mortality. Cancer. 2002;94:580-. CrossRef
  7. Altekruse S, Kosary C, Krapcho M, et al. SEER cancer statistics review, 1975-007. Bethesda, MD: National Cancer Institute; 2010.
  8. Duffy SW, Tabár L, Chen HH, et al. The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish countries. Cancer. 2002;95:458-9. CrossRef
  9. Swedish Organised Service Screening Evaluation Group. Reduction in breast cancer mortality from organized service screening with mammography. I. Further confirmation with extended data. Cancer Epidemiol Biomarkers Prev. 2006;15:45-1. CrossRef
  10. Tabár L, Vitak B, Chen HH, Yen MF, Duffy SW, Smith RA. Beyond randomized controlled trials: organized mammographic screening substantially reduces breast carcinoma mortality. Cancer. 2001;91:1724-1. CrossRef
  11. Hellquist BN, Duffy SW, Abdsaleh S, et al. Effectiveness of population-based service screening with mammography for women ages 40 to 49 years: evaluation of the Swedish Mammography Screening in Young Women (SCRY) cohort. Cancer. 2011;117:714-2. CrossRef
  12. Otto SJ, Fracheboud J, Looman CW, et al. Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet. 2003;361:1411-. CrossRef
  13. Paci E, EUROSCREEN Working Group. Summary of the evidence of breast cancer service screening outcomes in Europe and first estimate of the benefit and harm balance sheet. J Med Screen. 2012;19 Suppl 1:5-3. CrossRef
  14. Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA. 2009;302:1685-2. CrossRef
  15. Gotzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2011;1, CD001877.
  16. Lietzen LW, Sorensen GV, Ordin AG, et al. Survival of women with breast cancer in central and northern Denmark, 1998-009. Clin Epidemiol. 2011;3 Suppl 1:35-0. CrossRef
  17. Zahl PH, Maehlen J, Welch HG. The natural history of invasive breast cancers detected by screening mammography. Arch Intern Med. 2008;168:2311-. CrossRef
  18. Kopans DB, Smith RA, Duffy SW. Mammographic screening and “overdiagnosis- Radiology. 2011;260:616-0. CrossRef
  19. Jorgensen KJ, Keen JD, Gotzsche PC. Is mammographic screening justifiable considering its substantial overdiagnosis rate and minor effect on mortality? Radiology. 2011;260:621-. CrossRef
  20. Peckham CS, Dezateux C. Issues underlying the evaluation of screening programmes. Br Med Bull. 1998;54:767-8. CrossRef
  21. Penston J. Should we use total mortality rather than cancer specific mortality to judge cancer screening programmes? Yes. BMJ. 2011;343:d6395. CrossRef
  22. Steele R, Brewster D. Should we use total mortality rather than cancer specific mortality to judge cancer screening programmes? No. BMJ. 2011;343:d6397. CrossRef
  23. Espinas JA, Aliste L, Fernandez E, Argimon JM, Tresserras R, Borras JM. Narrowing the equity gap: the impact of organized versus opportunistic cancer screening in Catalonia (Spain). J Med Screen. 2011;18:87-0. CrossRef
  24. Jorgensen KJ, Gotzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ. 2009;339:b2587. CrossRef
  25. Ackrisson S, Andersson I, Janzon L, Manjer J, Garne JP. Rate of over diagnosis of breast cancer 15 years after end of Malm? mammographic screening trial: follow-up study. BMJ. 2006;332:689-2. CrossRef
  26. García Fernández A, Chabrera C, García Font M, et al. Positive versus negative sentinel nodes in early breast cancer patients: axillary or loco-regional relapse and survival. A study spanning 2000-012. Breast. 2013;22:902-. CrossRef
  27. Hubbard RA, Kerlikowske K, Flowers CI, Yankaskas BC, Zhu W, Miglioretti DL. Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. Ann Intern Med. 2011;155:481-2. CrossRef
  28. Ministerio de Sanidad y Consumo. Instituto de Salud “Carlos III- Agencia de Evaluación de Tecnologías Sanitarias (AETS). Cribado Poblacional de Cáncer de Mama mediante Mamografía. Madrid: AETS. Instituto de Salud “Carlos III- 1995.
  29. Warner E. Breast-cancer screening. N Engl J Med. 2011;365:1025-2. CrossRef
  30. Autier P, Boniol M, Gavin A, Vatten LJ. Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. BMJ. 2011;343:d4411. CrossRef
  31. Brewer NT, Salz T, Lillie SE. Systematic review: the long-term effects of false-positive mammograms. Ann Intern Med. 2007;146:502-0. CrossRef
  
• 作者单位：A. García Fernández (1) (16) (2)
  C. Chabrera (3) (4)
  M. García Font (5)
  M. Fraile (6)
  J. M. Lain (7)
  S. Gónzalez (8)
  C. Corral (7)
  M. Torras (1)
  J. Torres (9)
  M. Teixido (10)
  I Barco (1)
  R. López (11)
  C. Gónzalez (12)
  A. Pessarrodona (13)
  N. Giménez (14) (15)
  
  1. Breast Unit, Department of Gynecology, University Hospital of Mútua Terrassa, Research Foundation Mútua Terrassa, University of Barcelona, Barcelona, Spain
  16. OTC Programa Detección Precoz Cáncer de Mama, University Hospital of Mútua Terrassa, University of Barcelona, C/ Sant Antoni 20, 08221, Terrassa, Barcelona, Spain
  2. Department of Gynecology, Catalan Institute of Health, Mollet del Vallès, Barcelona, Spain
  3. Department of Nursing, School of Health Science, TechnoCampus Mataró-Maresme, Barcelona, Spain
  4. Department of Hematology/Oncology, Catalan Institute of Oncology, Barcelona, Spain
  5. University International of Catalunya, Barcelona, Spain
  6. Nuclear Medicine Department, Diagnostic Technology Center (CTD), University Hospital of Mútua Terrassa, Research Foundation Mútua Terrassa, University of Barcelona, Barcelona, Spain
  7. Breast Unit, Department of Gynecology, Hospital of Terrassa, Health Consortium of Terrassa, Terrassa, Spain
  8. Department of Hemato-oncology, University Hospital of Mútua Terrassa, Research Foundation Mútua Terrassa, University of Barcelona, Barcelona, Spain
  9. Department of Radiology, University Hospital of Mútua Terrassa, Research Foundation Mútua Terrassa, University of Barcelona, Barcelona, Spain
  10. Breast Unit, Department of Radiology, Hospital of Terrassa, Health Consortium of Terrassa, Terrassa, Spain
  11. Department of Health, Technical Secretary of CatSalut, Generalitat de Catalunya, Barcelona, Spain
  12. Breast Unit, Department of Pathology, University Hospital of Mútua Terrassa, Research Foundation Mútua Terrassa, University of Barcelona, Barcelona, Spain
  13. Department of Gynecology, CTD, University Hospital of Mútua Terrassa, Research Foundation Mútua Terrassa, University of Barcelona, Barcelona, Spain
  14. Research Unit, Research Foundation Mútua Terrassa, University of Barcelona, Barcelona, Spain
  15. Laboratory of Toxicology, Universitat Autònoma de Barcelona, Barcelona, Spain
  
• ISSN：1423-0380

文摘

Breast cancer screening programmes seem to bring about significant benefits, including decreased mortality, although they may also have some drawbacks such as false-negative and false-positive results. This study aims to compare the clinical outcome of a group of patients undergoing a breast cancer screening programme with that of a synchronous non-screened group of patients matched for age and follow-up period. We studied basic characteristics of epidemiology, immunohistochemistry, loco-regional relapse, distant metastases, disease-free interval and overall and specific mortality. We compared 510 patients in the screened group with 394 non-screened patients, along the period of 2002-012. Screening was applied on a target population of 49,847 and was based on double-projection, double-read mammograms. Two years were allowed per round. Overall participation for the five rounds considered was 75.2?%, with 86.5?% coverage, and a total cumulative population of 123,445. The non-participant women amounted 40,794. Tumour detection rate for the screened women was 3.8 per thousand (475/123,445), while the corresponding rate for non-participants was 9.4 per thousand (382/40,797). Incidence of luminal A subtype was 15?% higher in screened than that in non-screened patients (95?% confidence interval (CI) 8-2?%). Conversely, the triple-negative subtype was 6?% higher in the non-screened group (95?% CI 2-0?%). Incidence of breast conservative treatments and sentinel node biopsies was significantly higher in the screened group. Overall mortality was 2.6 times higher in non-screened than that in screened group (95?% CI 1.2-.6) After 10?years of experience with our own screening programme, we believe that included patients receive a benefit versus comparable non-screened breast cancer patients, with acceptable benefit-risk relation.